We at TargED have developed MICROLYSE, an innovative fusion-protein that has an antibody domain that recognizes microthrombi and an enzymatic domain that breaks them down.

At Toxys we strongly believe in bringing high quality information to our partners and clients. I strongly believe that the future for human safety assessment is not with simple tests that only provide a yes or no answers, but advanced in vitro models that provide reliable and relevant insight into the mechanism of action of novel chemicals and materials. We are committed to support our partners in understanding their latest compounds and in making the right decisions during R&D of novel products

At TrianecT, we develop StrokePointer: a fast pre-hospital solution for early stroke diagnosis.

Triangle Therapeutics strives to bring breakthrough technology to the clinic that blocks metastasis and thereby significantly enhancing success rates of first-line cancer treatments for patients suffering from metastatic cancers.

Targeting the cells that matter, enabling better cancer care. By identifying, selecting and isolating single cells, UFO Biosciences enables the identification of the important genes that are missed with current technology.

UPyTher’s mission is to provide custom drug delivery solutions that enable sustained localized administration of therapeutics.

By exploiting human organoids, VEO enhances the predictive value of antiviral testing over the current pre-clinical models.

VivArt-X develops synthetic support material for specific cell therapies. Our lead indication will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis.

The ambition of X-Heal Diagnostics is to improve lung health through fast, specific and non-invasive diagnosis of lung infections in different patient groups including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and tuberculosis patients.

Our revolutionary and novel device connects the artery and vein only during dialysis. At all other times it is closed, and normal circulation is restored. Our device, the Dynamic AVF will set the new gold standard for haemodialysis.